Eroglu, SemraCakmakliogullari, Elcin Kal2024-09-292024-09-2920211028-4559https://doi.org/10.1016/j.tjog.2021.09.012https://hdl.handle.net/20.500.14619/5382Objective: The aim of this study was to determine the serum adiponectin and interleukin-36 alpha (IL36a) levels in polycystic ovary syndrome (PCOS), and their relationship with obesity. Materials and methods: This observatory study included 80 PCOS patients and 58 controls. The clinical, biochemical, and hormonal parameters, and serum adiponectin and IL-36a levels of the patients were evaluated. Results: The serum IL-36a levels of the PCOS patients were significantly lower when compared to the control group, despite a similar mean body mass index (BMI) (P = 0.000). The adiponectin levels were significantly lower in the obese PCOS group when compared to the obese control group (P = 0.03). The plasma IL-36a level was positively correlated with adiponectin level, but negatively correlated with the serum LH level (P = 0.000 and P = 0.004, respectively). Using receiver operating characteristic analysis, the cut-off value of IL-36a was calculated as 0.815 for PCOS. In the multiple binary logistic regression analysis, IL-36a (OR [95% CI] 0.432 [0.303, 0.616], P < 0.001) and adiponectin (OR [95% CI] 1.044 [1.005, 1.084], P = 0.028) were determined to be significantly associated with PCOS. Conclusion: A reduced IL-36a level may play a role in the pathogenesis of ovulatory disfunction and insulin resistance in PCOS patients. Further studies are needed to understand the pathogenic and clinical significance of the IL-36 system in PCOS. (c) 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).eninfo:eu-repo/semantics/openAccessPolycystic ovary syndromeObesityInterleukin-36AdiponectinArticle10.1016/j.tjog.2021.09.0122-s2.0-851165350451022634794731Q2101860WOS:000722376100010Q4